Cenova was founded by Dr. Jun WU, one of the earliest successful biotechnology entrepreneur in China in 2010. Dr. Wu has since raised five funds in USD and RMB. 

After almost fifteen years of life science research experience in United States, Dr. Wu came back to China in 2001 and co-founded Shanghai Genomics, one of the earliest biotech companies in China, and grew it to become one of the most successful biotech companies established by returnees. He was instrumental in completing the successful merger between Shanghai Genomics and GNI Ltd, a series of subsequent fundraising events, and the initial public listing of the merged company on the Tokyo Stock Exchange (TSE) in 2007. Shanghai Genomics (GNI) was the first China biotech listed on a major international stock exchange, to successfully develop a billion-dollar drug (pirfenidone).

In addition to Dr. Wu’s successful entrepreneurial experience in China’s biotechnology and life science sector, he is also an outstanding scientist. He had obtained and successfully completed over thirty government funded research & development projects in China, including major programs under the auspices of the Chinese Ministry of Science and Technology, the Chinese National Science Foundation, Shanghai municipal and local government. He is a recipient of the prestigious ‘National Outstanding Young Scientist Award’ from the Chinese National Science Foundation. He has also been an adjunct professor at Shanghai Jiao Tong University since 2003. He has made important contributions in the field of immuno-oncology and has published over thirty high-quality research papers in professional journals, including Science, Nature, Nature Genetics, and PNAS.

Dr. Wu comes from a prestigious family of physicians, with members over three generations holding leadership positions in the China healthcare sector. He has a Ph.D. from the University of California San Francisco and studied at Fudan Medical School. He has been a long-term advisor to government healthcare policy-makers and is one of the first batch of government backed healthcare investors to facilitate the transformation of China’s healthcare industry.

Dr. Hai WU joined Cenova Capital as a Managing Partner in May 2019. He has extensive experience in investment and management and has held senior positions at multiple global leading investment, high technology and consulting firms. 

Prior to Cenova, Dr. Wu served as Managing Director of China at Temasek Holdings Ltd since May 2014, where he led the direct investments and fund investments in healthcare, telecommunications, media and technology (TMT), consumer and industrial. He also served as Managing Director at CITIC Private Equity from 2010 to 2012, where he led the firm's first buyout transaction and built its portfolio management capabilities. 

Dr. Wu has gained his extensive operation and management experience from his role as Chief Executive Officer at Ramaxel Technology (Shenzhen) Limited from 2012 to 2014 and his 11 year career at McKinsey & Co. from 1999 to 2010, where he served as global partner of McKinsey and Managing Partner of McKinsey Beijing office. 

He received a bachlor's degree in physiology from Peking University, a master's degree in business administration from Cornell Johnson School of Management and a doctoral degree in Neuroscience and Cell Biology from Rutgers University/UMDNJ. 

Dr. Kai ZHAO joined Cenova in 2014 as a Managing Partner with over 25 years’ experience in healthcare management and investment and has intimate knowledge of the healthcare services sector including hospital management and operations. Prior to Cenova, Dr. Zhao co-founded two hospital management and investment firms, SinoCare and Beijing JiaheGuokang Hospital Management and Investment Co. Ltd. In the past decade, he has led the acquisition and management of five hospitals in various parts of China, including four Tier 2 hospitals and two Tier 3 hospital. These hospitals have since achieved significant revenue growth under his leadership within two years.

Dr. Zhao has served as a financial advisor for Ciming Checkup, one of the largest Chinese preventive healthcare screening companies and completed the A-round investment by CDH. He was also the General Manager of Beijing Haiyinke Group, a bioscience investment firm and a leading biotech incubator in China. In Beijing Science and Technology Venture Investment Co. Ltd., as Head of Bioscience Investments, he led the investments in over ten life science and agriculture companies, including Beilu Pharmaceuticals (listed in ChiNext) and Shenzhen Chipscreen. Earlier in his career, Dr. Zhao spent fourteen years practicing medicine and held various positions of increasing responsibilities at the general hospital at Shenyang Military Region, a leading Tier 3 hospital in China. Dr. Zhao has a M.D. and Ph.D. from the Academy of Military Medical Sciences and the Fourth Military Medical University.

Mr. Adam WANG joined Cenova in 2014 with over 20 years of experience in designing and implementing marketing and sales strategies for new medical devices in China. He currently serves as the Chair of Board for Phoebus China, a Cenova portfolio company. Mr. Wang was the first employee of St. Jude Medical China, founding and managing the company's Cardiac Rhythm Management (CRM) division. He later led the CRM team in Boston Scientific China, reorganizing the team structure and redesigning the market strategy. Under his leadership, the revenue increased to 10 times its value within a mere of three years. During his term as General Manager of Optomed China, he founded Optomed's wholly owned Chinese subsidiary, introduced the company's world class non-mydriatic hand-held fundus camera to the country, and innovatively expanded the market from ophthalmology to diabetic management.

Earlier in his career, Mr. Wang worked in various technical service roles at Medtronic and 3M in China. He co-founded MHC, a healthcare communication company, developing China market strategies for multinational pharmaceutical and device companies later was acquired by CMPMedia successfully.

Mr. Wang began his career in clinical practice as surgeon at Shanghai Huadong Hospital after graduating from Shanghai Medical College of Fudan University. He also holds an EMBA from China Europe International Business School and a Certificate in Strategic Marketing from the University of Michigan.

Dr. Tao HUANG has over 20 years of combined experience in biomedical research, legal, academia and the life sciences industry. At Cenova, he oversees the intellectual property (“IP”) strategy for the portfolio companies. Prior to Cenova, Dr. Huang was an attorney at several prestigious law firms in the US, including Wilson Sonsini Goodrich and Rosati, and Morgan Lewis and Bockius. He has advised companies and investors in the biotechnology and pharmaceutical industries on a broad range of business and legal issues, including patent counselling, licensing, litigation, venture financing, mergers and acquisitions, and initial public offerings. Dr. Huang has provided IP and legal representation to several notable business transactions, including Takeda’s licensing and collaboration deal with Alnylam relating to RNAi therapeutics, Ion Torrent’s acquisition by Life Technologies, and QuantaLife’s acquisition by Bio-Rad Laboratories.

Dr. Huang received a B.Sc. in Biophysics from Nankai University, a Ph.D. in Biochemistry from Peking Union Medical College's Chinese Academy of Medical Sciences, a J.D. from the University of Michigan Law School and obtained his post-doctoral training in molecular biology and biochemistry from Princeton University. Dr. Huang is a registered United States Patent and Trademark Office attorney in the state of California.

Dr. Walter LAU has over 20 years of experience in life sciences, including biomedical research, sales and marketing, corporate business development, venture start-ups, management of venture backed private companies and private equity investment in Chinese healthcare companies. 

Prior to co-founding Cenova, Dr. Lau was at Fidelity Asia Ventures, where he specialized in healthcare investment in China. This included the series A investment in Hile, an animal healthcare company, together with New Horizon Capital and Vivo Ventures. He was also involved with board responsibilities at the portfolio companies. In Onyx Pharmaceuticals, Dr. Lau was responsible for corporate development and he completed various mergers and acquisitions and licensing deals globally.

Dr. Lau have also held positions with increasing responsibilities in Corporate Business Development at Bristol-Myers Squibb, focusing on global business development and mergers and acquisitions. He was in-charge of global licensing activities for Bristol-Myers Squibb’s (“BMS”) oncology franchise and led the external alliance efforts to build BMS early oncology pipeline. Dr. Lau completed transactions ranging from acquiring novel therapeutics (e.g., Ipilimumab), in-licensing of novel technologies in biologics and companion diagnostics (e.g., ImClone and Genomic Health), establishing and managing strategic collaborations (e.g., Exelixis), and out-licensing of BMS's non-core assets. He was head of business development of the former DuPont Pharma’s division after its acquisition by BMS. Prior to BMS, Dr. Lau held positions in field sales, product marketing, and business development at GlaxoSmithKline in the United States. His extensive experience and knowledge in biopharmaceutical innovation and business development is a great asset to Cenova when making investments in and managing innovative pharmaceutical companies.

Mr BAI Chengliang is a Operating Partner at Cenova Capital, with extensive knowledge in the management and operations of hospitals in China. He is a Director of the Chinese Non-Government Medical Institutions Association and an Executive Director of the Shanghai Association of Non-Government Medical Institutions.

Mr. Bai has worked as a Director and General Manager in various public and private hospitals in China. He was a Senior Manager in various sizeable medical groups including Shanghai Grand Enterprises Medical Group and Shanghai Medea Hospital Group. Mr. Bai accumulated his unique experiences in running the operations of ophthalmology hospitals as the General Manager and President of Shanghai Heping Eye Hospital and Shanghai Ren-Ai Hospital. He was previously an Operating Partner at CITIC Capital.

Mr. Bai graduated from Zhejiang University majoring in Clinical Medicine and received his EMBA from Zhejiang University.